Due to strict regulation on Neuropozyne, most biotech and pharmaceutical companies shy away from producing their own anti-rejections drugs, but a critical shortage of Neuropozyne in 2027 lead Zaaphire Biotech to offer Riezene as a cheaper alternative. Zapphire Biotech contacted several LIMB clinics to be included in clinical trials of the new anti-rejection drug. The clinic in Panama City refused, citing patient health concerns from reports of Riezene having adverse effects on users.
Attributes | Values |
---|---|
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
abstract |
|
is Products of |